$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur

$acur Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000114420417026909 Filed on May 12, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2016 Q1
Revenue	$2.717M	$3.765M	$224.0K
YoY Change	1112.95%	40.54%	-95.82%
Cost Of Revenue	$130.0K	$140.0K	$100.0K
YoY Change	30.0%	40.0%	-60.78%
Gross Profit	$2.590M	$3.620M	$120.0K
YoY Change	2058.33%	40.31%	-97.65%
Gross Profit Margin	95.33%	96.15%	53.57%
Selling, General & Admin	$1.296M	$1.120M	$2.246M
YoY Change	-42.3%	-56.76%	-2.22%
% of Gross Profit	50.04%	30.94%	1871.67%
Research & Development	$711.0K	$770.0K	$1.014M
YoY Change	-29.88%	10.0%	5.19%
% of Gross Profit	27.45%	21.27%	845.0%
Depreciation & Amortization	$80.00K	$90.00K	$34.00K
YoY Change	135.29%	0.0%	13.33%
% of Gross Profit	3.09%	2.49%	28.33%
Operating Expenses	$2.007M	$1.900M	$3.260M
YoY Change	-38.44%	-42.25%	-0.03%
Operating Profit	$582.0K	$1.729M	-$3.138M
YoY Change	-118.55%	-343.52%	-307.54%
Interest Expense	$177.0K	-$200.0K	$249.0K
YoY Change	-28.92%	-4.76%	-19.16%
% of Operating Profit	30.41%	-11.57%
Other Income/Expense, Net	-$177.0K	$0.00	-$246.0K
YoY Change	-28.05%		-9.89%
Pretax Income	$405.0K	$1.530M	-$3.384M
YoY Change	-111.97%	-266.3%	-373.12%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%	0.0%
Net Earnings	$405.0K	$1.534M	-$3.384M
YoY Change	-111.97%	-267.47%	-373.12%
Net Earnings / Revenue	14.91%	40.74%	-1510.71%
Basic Earnings Per Share	$0.03	$0.13	-$0.28
Diluted Earnings Per Share	$0.03	$0.13	-$0.28
COMMON SHARES
Basic Shares Outstanding	11.91M shares		11.84M shares
Diluted Shares Outstanding	12.08M shares		11.84M shares

Balance Sheet

Concept	2017 Q1	2016 Q4	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.840M	$2.681M	$10.97M
YoY Change	-65.0%	-79.88%	-22.8%
Cash & Equivalents	$3.843M	$2.681M	$782.0K
Short-Term Investments		$0.00	$7.690M
Other Short-Term Assets	$2.800M	$2.770M	$300.0K
YoY Change	833.33%	-4.81%	-3.23%
Inventory	$0.00	$309.0K	$200.0K
Prepaid Expenses
Receivables	$40.00K	$100.0K	$140.0K
Other Receivables	$50.00K	$50.00K	$30.00K
Total Short-Term Assets	$6.738M	$5.910M	$11.63M
YoY Change	-42.06%	-58.19%	-22.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$739.0K	$867.0K	$1.030M
YoY Change	-28.25%	-14.41%	6.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$180.0K
YoY Change		-100.0%	20.0%
Total Long-Term Assets	$2.118M	$2.298M	$2.790M
YoY Change	-24.09%	-18.68%	-4.12%
TOTAL ASSETS
Total Short-Term Assets	$6.738M	$5.910M	$11.63M
Total Long-Term Assets	$2.118M	$2.298M	$2.790M
Total Assets	$8.856M	$8.208M	$14.42M
YoY Change	-38.59%	-51.61%	-19.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$209.0K	$77.00K	$380.0K
YoY Change	-45.0%	-30.0%	137.5%
Accrued Expenses	$1.040M	$703.0K	$1.210M
YoY Change	-14.05%	24.65%	14.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.798M	$2.376M	$2.575M
YoY Change	8.66%	2.41%	8.65%
Total Short-Term Liabilities	$4.403M	$3.487M	$4.430M
YoY Change	-0.61%	7.49%	17.82%
LONG-TERM LIABILITIES
Long-Term Debt	$2.142M	$2.979M	$4.810M
YoY Change	-55.47%	-45.14%	-34.56%
Other Long-Term Liabilities	$600.0K	$560.0K	$430.0K
YoY Change	39.53%	43.59%	79.17%
Total Long-Term Liabilities	$2.142M	$2.979M	$5.240M
YoY Change	-59.12%	-45.14%	-30.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.403M	$3.487M	$4.430M
Total Long-Term Liabilities	$2.142M	$2.979M	$5.240M
Total Liabilities	$7.143M	$7.025M	$9.670M
YoY Change	-26.13%	-22.47%	-14.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$374.3M	-$374.7M
YoY Change		2.01%
Common Stock	$376.0M	$375.9M
YoY Change		0.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.713M	$1.183M	$4.750M
YoY Change
Total Liabilities & Shareholders Equity	$8.856M	$8.208M	$14.42M
YoY Change	-38.59%	-51.61%	-19.31%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2016 Q1
OPERATING ACTIVITIES
Net Income	$405.0K	$1.534M	-$3.384M
YoY Change	-111.97%	-267.47%	-373.12%
Depreciation, Depletion And Amortization	$80.00K	$90.00K	$34.00K
YoY Change	135.29%	0.0%	13.33%
Cash From Operating Activities	$1.298M	$1.780M	-$1.920M
YoY Change	-167.6%	-267.92%	-188.48%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	$49.00K
YoY Change	-100.0%		6.52%
Acquisitions
YoY Change
Other Investing Activities	$310.0K	$0.00	$3.180M
YoY Change	-90.25%	-100.0%	241.94%
Cash From Investing Activities	$309.0K	$0.00	$3.130M
YoY Change	-90.13%	-100.0%	255.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$445.0K	-870.0K	-410.0K
YoY Change	8.54%	8.75%
NET CHANGE
Cash From Operating Activities	$1.298M	1.780M	-1.920M
Cash From Investing Activities	$309.0K	0.000	3.130M
Cash From Financing Activities	-$445.0K	-870.0K	-410.0K
Net Change In Cash	$1.162M	910.0K	800.0K
YoY Change	45.25%	-208.33%	-73.77%
FREE CASH FLOW
Cash From Operating Activities	$1.298M	$1.780M	-$1.920M
Capital Expenditures	$0.00	-$10.00K	$49.00K
Free Cash Flow	$1.298M	$1.790M	-$1.969M
YoY Change	-165.92%	-268.87%	-192.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	10
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11883000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11834000	shares
CY2017Q1	acur	Increase Decrease In Sales Return Liability IncreaseDecreaseInSalesReturnLiability	51000	USD
CY2016Q1	acur	Increase Decrease In Sales Return Liability IncreaseDecreaseInSalesReturnLiability	2000	USD
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11883000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11834000	shares
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	117000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	8000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	117000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-17000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	150000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	57000	USD
CY2016Q4	acur	Accrued Cost Sharing Expenses Clinical Studies AccruedCostSharingExpensesClinicalStudies	150000	USD
CY2017Q1	acur	Proceeds From Sale Of Inventory ProceedsFromSaleOfInventory	206000	USD
CY2016Q1	acur	Proceeds From Sale Of Inventory ProceedsFromSaleOfInventory	0	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	75000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	110000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	103000	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2654000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2807000	USD
CY2016Q4	acur	Impairment Of Property Plant And Equipment Reserve ImpairmentOfPropertyPlantAndEquipmentReserve	-82000	USD
CY2016Q4	acur	Accrued Cost Sharing Expenses AccruedCostSharingExpenses	150000	USD
CY2017Q1	acur	Advanced Expenses Reimbursement AdvancedExpensesReimbursement	209000	USD
CY2016Q4	acur	Advanced Expenses Reimbursement AdvancedExpensesReimbursement	0	USD
CY2017Q1	acur	Agreement Termination Notice Description AgreementTerminationNoticeDescription	Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.
CY2017Q1	acur	Accrued Cost Sharing Expenses AccruedCostSharingExpenses	269000	USD
CY2017Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	50000	USD
CY2017Q1	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	100000	USD
CY2016	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	50000	USD
CY2016	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	47200000	USD
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	138800000	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2016	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2100000	USD
CY2017Q1	acur	Share Based Compensation Expense Recognized In Operations ShareBasedCompensationExpenseRecognizedInOperations	117000	USD
CY2016Q1	acur	Share Based Compensation Expense Recognized In Operations ShareBasedCompensationExpenseRecognizedInOperations	150000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	70000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	309000	USD
CY2017Q1	acur	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6343000	USD
CY2016Q1	acur	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3282000	USD
CY2016Q4	acur	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5181000	USD
CY2015Q4	acur	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2485000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	782000	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2500000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	USD
CY2017Q1	acur	License Agreement Option Products Description LicenseAgreementOptionProductsDescription	In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing pseudoephedrine (“PSE”) and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1456000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1324000	shares
CY2017Q1	acur	Accrued Cost Sharing Expenses Clinical Studies AccruedCostSharingExpensesClinicalStudies	269000	USD
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2016Q4	us-gaap	Assets Current AssetsCurrent	5910000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	268000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	301000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	309000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	0	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	739000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	867000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1431000	USD
CY2017Q1	us-gaap	Assets Assets	8856000	USD
CY2016Q4	us-gaap	Assets Assets	8208000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	209000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	77000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1040000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	703000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	19000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	27000	USD
CY2017Q1	acur	Sales Returns Liability Current SalesReturnsLiabilityCurrent	302000	USD
CY2016Q4	acur	Sales Returns Liability Current SalesReturnsLiabilityCurrent	304000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2798000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2376000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	7143000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	7025000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	119000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	118000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	375887000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	375763000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-374293000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-374698000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	1713000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1183000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8856000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8208000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4403000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3487000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2142000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2979000	USD
CY2017Q1	acur	Longterm Portion Of Accrued Interest LongtermPortionOfAccruedInterest	598000	USD
CY2016Q4	acur	Longterm Portion Of Accrued Interest LongtermPortionOfAccruedInterest	559000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	6738000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1379000	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2500000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2500000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2681000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3843000	USD
CY2017Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	6000	USD
CY2016Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	23000	USD
CY2017Q1	acur	Collaboration Revenue Receivable CollaborationRevenueReceivable	36000	USD
CY2016Q4	acur	Collaboration Revenue Receivable CollaborationRevenueReceivable	79000	USD
CY2017Q1	acur	Royalty Receivable RoyaltyReceivable	52000	USD
CY2016Q4	acur	Royalty Receivable RoyaltyReceivable	50000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	17000	USD
CY2017Q1	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	128000	USD
CY2016Q1	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	102000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	711000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1014000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1296000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2246000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	582000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3138000	USD
CY2017Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1000	USD
CY2016Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	27000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	178000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	249000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	405000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3384000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	405000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3384000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	70000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	405000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3314000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-177000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-246000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11907000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11837000	shares
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	ACURA PHARMACEUTICALS, INC
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	107000	USD
CY2017Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2500000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	74000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	107000	USD
CY2016Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	0	USD
CY2017Q1	us-gaap	Revenues Revenues	2717000	USD
CY2016Q1	us-gaap	Revenues Revenues	224000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-121000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	265000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	591000	USD
CY2016Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	99000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2017Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	445000	USD
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000786947
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	797000	USD
CY2017Q1	acur	Provision For Sales Returns ProvisionForSalesReturns	49000	USD
CY2016Q1	acur	Provision For Sales Returns ProvisionForSalesReturns	39000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3177000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	309000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3128000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1162000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	2135000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12083000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11837000	shares
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	36000	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	100000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	3362000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	30000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	40000	USD
CY2017Q1	acur	Amortization Of Bond Premium In Marketable Securities AmortizationOfBondPremiumInMarketableSecurities	0	USD
CY2016Q1	acur	Amortization Of Bond Premium In Marketable Securities AmortizationOfBondPremiumInMarketableSecurities	19000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	52000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	52000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-12000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-103000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-74000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	33000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	132000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	337000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1298000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1922000	USD
CY2017Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	74000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-445000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-409000	USD
CY2016Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	409000	USD
CY2017Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	USD
CY2016Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-24000	USD
CY2017Q1	acur	Increase Decrease In Collaboration Revenue Receivable IncreaseDecreaseInCollaborationRevenueReceivable	-43000	USD
CY2016Q1	acur	Increase Decrease In Collaboration Revenue Receivable IncreaseDecreaseInCollaborationRevenueReceivable	0	USD
CY2017Q1	acur	Increase Decrease In Royalty Receivable IncreaseDecreaseInRoyaltyReceivable	2000	USD
CY2016Q1	acur	Increase Decrease In Royalty Receivable IncreaseDecreaseInRoyaltyReceivable	0	USD
CY2017Q1	acur	Cash Cash Equivalent And Marketable Securities CashCashEquivalentAndMarketableSecurities	3800000	USD
CY2017Q1	acur	Working Capital WorkingCapital	200000	USD
CY2017Q1	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	2500000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	243000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	341000	USD
CY2016Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	98000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1833000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1858000	USD
CY2017Q1	acur	Impairment Of Property Plant And Equipment Reserve ImpairmentOfPropertyPlantAndEquipmentReserve	-82000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	173000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	116000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	173000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	232000	USD
CY2017Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	445000	USD
CY2017Q1	acur	Debt Instrument Classification Amount DebtInstrumentClassificationAmount	0	USD
CY2017Q1	acur	Other Accrued Taxes Current OtherAccruedTaxesCurrent	6000	USD
CY2016Q4	acur	Other Accrued Taxes Current OtherAccruedTaxesCurrent	1000	USD
CY2017Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	18000	USD
CY2016Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	16000	USD
CY2016Q4	acur	Accrued Other Professional Fees Current AccruedOtherProfessionalFeesCurrent	131000	USD
CY2017Q1	acur	Marketing Advertising And Promotion MarketingAdvertisingAndPromotion	5000	USD
CY2016Q4	acur	Marketing Advertising And Promotion MarketingAdvertisingAndPromotion	10000	USD
CY2017Q1	acur	Accrued Other Professional Fees Current AccruedOtherProfessionalFeesCurrent	136000	USD
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10000000	USD
CY2013Q4	acur	Debt Default Long Term Debt Percentage DebtDefaultLongTermDebtPercentage	0.1335	pure
CY2017Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	260000	USD
CY2017Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-12-01
CY2015Q1	acur	Debt Instrument Cash Maintenance DebtInstrumentCashMaintenance	2500000	USD
CY2016Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6000000	USD
CY2017Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	50000	USD
CY2017Q1	acur	Debt Consulting Placement Fee DebtConsultingPlacementFee	100000	USD
CY2017Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.1016	pure
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5500000	USD
CY2017Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5055000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	98000	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	78000	USD
CY2017Q1	acur	Classification Of Debt Discount Premium ClassificationOfDebtDiscountPremium	0	USD
CY2016Q4	acur	Debt Instrument Issuance Costs DebtInstrumentIssuanceCosts	-47000	USD
CY2017Q1	acur	Amortization Expense Of Debt Instrument Issuance Costs AmortizationExpenseOfDebtInstrumentIssuanceCosts	10000	USD
CY2017Q1	acur	Debt Instrument Issuance Costs DebtInstrumentIssuanceCosts	-37000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	4940000	USD
CY2017Q1	acur	Classification Of Deferred Debt Issuance Costs ClassificationOfDeferredDebtIssuanceCosts	0	USD
CY2017Q1	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	20000	USD
CY2016Q1	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	26000	USD
CY2017Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	10000	USD
CY2016Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	14000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	209000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2077000	USD
CY2013Q4	us-gaap	Secured Debt SecuredDebt	10000000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	335000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	64000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	271000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.18
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.36
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.14
CY2017Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	11881000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	11832000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	5000	shares
CY2017Q1	acur	Incremental Common Shares Attributable To Conversion Of Common Stock IncrementalCommonSharesAttributableToConversionOfCommonStock	11881000	shares
CY2016Q1	acur	Incremental Common Shares Attributable To Conversion Of Common Stock IncrementalCommonSharesAttributableToConversionOfCommonStock	11832000	shares
CY2017Q1	acur	Incremental Common Shares Attributable To Restricted Stock IncrementalCommonSharesAttributableToRestrictedStock	202000	shares
CY2016Q1	acur	Incremental Common Shares Attributable To Restricted Stock IncrementalCommonSharesAttributableToRestrictedStock	5000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	148000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2978000	USD
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Trading Symbol TradingSymbol	ACUR
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11883339	shares
CY2017Q1	us-gaap	Interest Payable Current InterestPayableCurrent	35000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7000	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	27000	USD
CY2017Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	32000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	621000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	569000	USD
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01

Files In Submission

Name	View Source	Status
0001144204-17-026909-index-headers.html	Edgar Link	pending
0001144204-17-026909-index.html	Edgar Link	pending
0001144204-17-026909.txt	Edgar Link	pending
0001144204-17-026909-xbrl.zip	Edgar Link	pending
acur-20170331.xml	Edgar Link	completed
acur-20170331.xsd	Edgar Link	pending
acur-20170331_cal.xml	Edgar Link	unprocessable
acur-20170331_def.xml	Edgar Link	unprocessable
acur-20170331_lab.xml	Edgar Link	unprocessable
acur-20170331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v464992_10q.htm	Edgar Link	pending
v464992_ex10-1.htm	Edgar Link	pending
v464992_ex10-2.htm	Edgar Link	pending
v464992_ex31-1.htm	Edgar Link	pending
v464992_ex31-2.htm	Edgar Link	pending
v464992_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur

2017 Q1 Form 10-Q Financial Statement

#000114420417026909 Filed on May 12, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACUR ACURA PHARMACEUTICALS, INC Stock $acur

2017 Q1 Form 10-Q Financial Statement

#000114420417026909 Filed on May 12, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur